Cicaprost and the type IV phosphodiesterase inhibitor, rolipram, synergize in suppression of tumor necrosis factor- synthesis

Author： Greten T.F.   Sinha B.   Haslberger C.   Eigler A.   Endres S.  

Publisher： Elsevier

ISSN： 0014-2999

Source： European Journal of Pharmacology, Vol.299, Iss.1, 1996-03, pp. : 229-233

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Does Tumor Necrosis Factor- (TNF- ) Contribute to Myocardial Reperfusion Injury in Anesthetized Rats? - positive inotropic and phosphodiesterase inhibitory effects of Org 30029, milrinone and rolipram

By Jonsson J.   McVey M.   Perrone M.H.   Clark K.L.  

General Pharmacology, Vol. 32, Iss. 1, 1999-01 ,pp. : 41-45

Elsevier

Access to resources Recommend Favorite

The Phosphodiesterase Type 4 Inhibitor, Rolipram, Enhances Glucocorticoid Receptor Function

By Miller A.H.   Vogt G.J.   Pearce B.D.  

Neuropsychopharmacology, Vol. 27, Iss. 6, 2002-12 ,pp. : 939-948

Elsevier

Access to resources Recommend Favorite

Suppression of oro-facial movements by rolipram, a cAMP phosphodiesterase inhibitor, in rats chronically treated with haloperidol

By Sasaki H.   Hashimoto K.   Inada T.   Fukui S.   Iyo M.  

European Journal of Pharmacology, Vol. 282, Iss. 1, 1995-08 ,pp. : 71-76

Elsevier

Access to resources Recommend Favorite

Function and Regulation of Tumor Necrosis Factor Receptor Type 2

By  

Current Medicinal Chemistry, Vol. 11, Iss. 16, 2004-08 ,pp. : 2205-2212

Bentham Science Publishers

Access to resources Recommend Favorite

Anti-inflammatory and analgesic effects of the phosphodiesterase 4 inhibitor rolipram in a rat model of arthritis

By Francischi J.N.   Yokoro C.M.   Poole S.   Tafuri W.L.   Cunha F.Q.   Teixeira M.M.  

European Journal of Pharmacology, Vol. 399, Iss. 2, 2000-07 ,pp. : 243-249

Elsevier

Access to resources Recommend Favorite